



LEARNING

Diabetes, Heart Failure and CKD- three pillars of CRM (Part 1)

Wednesday 30 November 2022

DM/CKD/HF - bringing management together and future directions'

Prof Ketan Dhatariya

This webinar was funded by Boehringer Ingelheim and Lilly Diabetes Alliance (The Alliance).




RCGP maintain editorial control over all webinar content.



Most Cases of CKD Are Not Due to Diabetes

Age-standardised global prevalence rate of CKD by cause per 100,000 persons in 2016¹



58%
of CKD cases are
not caused by type 2
diabetes

42%
of CKD cases are
caused by type 2
diabetes




Overlap Between Co-Morbidities

~1/3 of people with type 2 diabetes have cardiovascular disease

There are good trial data addressing individual components of this triad

2-5 times more likely to develop HF if you have T2D




CKD affects up to 50% of HF patients




~30–40% of adults with diabetes have CKD



CVD Prevalence in those ± CKD




Outcomes Worsen as eGFR Deteriorates




NG28

NICE recommends metformin only as first line treatment for type 2 diabetes patients not at high risk of cardiovascular disease




NG28

NICE recommends SGLT2i's as a first-line treatment with metformin for type 2 diabetes patients at high-risk of CVD




NG28


NICE recommends SGLT2i's as a first-line treatment with metformin for type 2 diabetes patients with established CVD




EASD/ADA Consensus 2022





EASD/ADA Consensus 2022




But Why?? How Do SGLT2 Inhibitors Work?




How Are They Beneficial?



Empagliflozin – Mortality Benefit Within 60 Days



Dapagliflozin – Reduces CV Death and HF



26%
RRR


4.9%
ARR

NNT=21



Dapagliflozin – Reduces Progression of CKD

Primary endpoint: declining kidney function, ESKD and renal or CV death





LEARNING

Diabetes, Heart Failure and CKD- three pillars of CRM (Part 1)

Wednesday 30 November 2022

DM/CKD/HF - bringing management together and future directions'

ketan.dhatariya@nnuh.nhs.uk
[@ketandhatariya](https://twitter.com/ketandhatariya)
[@JBDSIP](https://twitter.com/JBDSIP)

This webinar was funded by Boehringer Ingelheim and Lilly Diabetes Alliance (The Alliance).



RCGP maintain editorial control over all webinar content.